The Topical Corticosteroid Classification Called Into Question:Towards a New Approach.
Fiche publication
Date publication
février 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HUMBERT Philippe
Tous les auteurs :
Humbert P, Guichard A
Lien Pubmed
Résumé
In 1952, Sulzberger et al. achieved a breakthrough in the field of dermatology by reporting for the first time the efficacy of topical corticosteroids (TCS) on eczematous dermatitis. Nowadays, TCS are widely used, at any age, to treat a wide variety of common dermatologic disorders i.e. contact dermatitis, psoriasis, atopic dermatitis, or to treat skin manifestations of auto-immune diseases. These topical formulations have several effects such as anti-inflammatory and immunomodulator, antiproliferative, anti-pruritus and vasoconstrictor properties. Despite proven safety and tolerability, TCS may induce local and systemic side effects such as cutaneous atrophy, hypothalamic-pituitary-adrenal (HPA) axis suppression, iatrogenic Cushing's, steroid rosacea, and allergy. This article is protected by copyright. All rights reserved.
Référence
Exp Dermatol. 2015 Feb 24